Edition:
India

Valneva Reports Positive End-Of-Phase 2 Chikungunya Meeting With The U.S. FDA


Wednesday, 25 Mar 2020 

March 25 (Reuters) - Valneva SE ::VALNEVA REPORTS POSITIVE END-OF-PHASE 2 CHIKUNGUNYA MEETING WITH THE U.S. FDA; SETS STAGE FOR PHASE 3 STUDY.STUDY INITIATION AS SOON AS COVID-19 SITUATION PERMITS, CURRENTLY ANTICIPATED FOR Q4 2020.PRIMARY ENDPOINT ANALYSIS IS EXPECTED SIX MONTHS THEREAFTER.FINAL ANALYSIS WILL BE CONDUCTED AT DAY 180 (SIX MONTHS AFTER IMMUNIZATION).TOTAL DURATION OF STUDY IS EXPECTED TO BE NINE MONTHS.